Compare National Beverage Corp. (FIZZ) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs GSK plc — how do they compare? National Beverage Corp. trades at $30.88 (market cap $2.89B), while GSK plc trades at $46.87 (market cap $91.88B). The key difference: GSK plc is far larger — about 31.8× National Beverage Corp.'s market cap, and GSK plc pays a 3.9% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and GSK plc for 93 Days on average.
| FIZZ | GSK | |
|---|---|---|
Market Cap | $2.89B | $91.88B |
Volume | 553,950 | 7,730,529 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $61.18 |
52-Week Low | $29.20 | $43.24 |
Typical Hold Time | 33 Days | 93 Days |
Enterprise Value | $2.84B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $29.60, down 1.4% with bearish technical signals. The company reported stagnant $1.2B revenue but improved net margins to 15.55% in 2025. Recent earnings misses and a $3.25 special dividend highlight mixed performance. Technical indicators show strong bearish momentum with support at $29 and resistance at $30.
Outlook remains challenged by margin pressure and growth stagnation. While strong profitability metrics (40% ROE) provide support, analyst sentiment is cautious with 50% sell ratings. Key risks include competitive pressures and input cost inflation affecting gross margins.
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
